<\/td>

Steve and Andrew came back with a ton of new data on GLP-1 Agonist therapies from the 71^st Scientific Sessions of the ADA. We turned over these articles, abstracts, posters and presentations to our interns for them to get down to what really matters. They have three articles focusing on new developments with Liraglutide, Exenatide and a not-ready-for-sale Lixisenatide for you to review.

In this week's Case Study we continue to look at our patient Mr. Walker and which pharmacologic therapy options for type 2 diabetes would improve his glucose levels without being contraindicated due to his renal insufficiency or cardiovascular disease.

For the first time we take a look at the data from our GLP-1 Survey and break it down by profession. Be sure to check out what your peers think about GLP-1.

In order to increase compliance and improve efficacy, there is an experimental long acting exenatide once monthly injectable suspension in the pipeline. This long acting formulation is currently in phase-2 trial and has showed promising results in controlling A1C in type 2 diabetes patients....

The investigational drug Lyxumia® (lixisenatide), a once daily GLP-1 agonist, is making progress as a newer drug in this increasingly crowded class of drugs. Data from four studies of the GetGoal Phase III clinical program was presented at the ADA sessions....

Adding Insulin to Metformin and Liraglutide: A New Sequence of Medication Therapy for Type-2 Diabetes Patients

A new clinical study shows for the first time that the addition of long-acting insulin to the medication regimen of Metformin plus Victoza (liraglutide) allowed patients to reach an A1c goal of less-than-7% with only minor increases in hypoglycemic episodes. Patients who did not reach their A1c target on Metformin plus Victoza alone did reach their goal with gradual addition of Levemir (insulin detemir). Prior to this study there had not been a trial measuring the effects of adding long-acting insulin to insulin-naïve patients who were using a GLP-1 receptor agonist drug, the drug class to which Victoza belongs....

Case Presentation, Part 2: Mr. Walker is a 59-year-old Caucasian who presents for evaluation of his type 2 diabetes, discovered 6 months ago by a random glucose measurement of 250 mg/dL using his wife's blood glucose meter. Mr. Walker visited his physician a few days later at his wife's request and had an A1C measurement of 7.5%....

We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered....

To help introduce this new series on GLP-1 therapy, we've gathered together commentary and insight from leading experts across the field: Anne L. Peters, MD, Ralph A. DeFronzo, MD, Alan J. Garber, MD, PhD, Robert R. Henry, MD, Richard Bergenstal, MD, and others share their thoughts....

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....

Once-Daily Lixisenatide meets primary efficacy endpoint with fewer hypoglycemias than Exenatide twice-daily....